日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)

一项针对局部晚期头颈部鳞状细胞癌患者的 1 期研究，评估 berzosertib (M6620, VX-970) 与顺铂和放射治疗的疗效 (ETCTN 9950)

期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.70346
Bhatia, Aarti; Chen, Zhengjia; Zhang, Yuji; Bruce, Justine Yang; Arnold, Susanne; Kaur, Varinder; Riess, Jonathan W; Fenton, Moon; Burtness, Barbara; Saba, Nabil F; Tara, Harold; Steuer, Conor E; Shin, Dong M; Wasp, Garrett; Davis, Thomas H; Patel, Malini; Schmitz, John C; Bhateja, Priyanka; Diavolitsis, Virginia; Zandberg, Dan P; Mitchell, Darrion L; Kiesel, Brian F; Kunos, Charles; Gore, Steven D; Carducci, Michael; Beumer, Jan H; Owonikoko, Taofeek K
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer

Enfortumab Vedotin治疗既往接受过治疗的晚期头颈癌患者的II期临床试验

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO.24.00646
Swiecicki, Paul L; Yilmaz, Emrullah; Rosenberg, Ari Joseph; Fujisawa, Takao; Bruce, Justine Yang; Meng, Changting; Wozniak, Michele; Zhao, Yongyun; Mihm, Michael; Kaplan, Jason; Gorla, Seema; Geiger, Jessica L
肿瘤
肿瘤免疫
头颈癌
发表日期：2025
文献求助 收藏

Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study

碘泊辛 I 131 (CLR 131) 联合外照射放射治疗复发或转移性头颈癌的安全性和毒性：一项 1 期单中心、开放标签、单臂、剂量递增和剂量扩展研究的结果

期刊:EBioMedicine
影响因子:10.8
doi:10.1016/j.ebiom.2024.105496
Bruce, Justine Yang; Burr, Adam; Kimple, Randall J; Adam, David P; Yu, Menggang; Piaskowski, Shari M; Glazer, Tiffany A; Hill, Patrick; Hartig, Gregory K; McCulloch, Timothy M; Wieland, Aaron M; Trask, Diana; Oliver, Kate; Longcor, Jarrod; Rogus-Pulia, Nicole; Cho, Steve Y; Bednarz, Bryan; Harari, Paul M
肿瘤
毒理研究
肿瘤免疫
头颈癌
发表日期：2025
文献求助 收藏

Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer.

Axl 对 NK 细胞活性的调节在头颈癌中创造了免疫抑制性肿瘤免疫微环境

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17060994
Kostecki Kourtney L, Harmon Regan L, Iida Mari, Harris Madelyn A, Crossman Bridget E, Bruce Justine Yang, Salgia Ravi, Wheeler Deric L
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

阿昔替尼联合克唑替尼治疗转移性肾细胞癌或其他晚期实体瘤患者的Ib期研究

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2018-0749
Michaelson, M Dror; Gupta, Shilpa; Agarwal, Neeraj; Szmulewitz, Russell; Powles, Thomas; Pili, Roberto; Bruce, Justine Yang; Vaishampayan, Ulka; Larkin, James; Rosbrook, Brad; Wang, Erjian; Murphy, Danielle; Wang, Panpan; Lechuga, Maria Josè; Valota, Olga; Shepard, Dale R
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2019
文献求助 收藏

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.

使用 FLT PET/CT 对采用 X-82 和多西他赛序贯联合治疗的晚期实体恶性肿瘤进行药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-018-3599-3
Scarpelli Matthew, Rampurwala Murtuza, Eickhoff Jens, Carmichael Lakeesha, Heideman Jennifer, Binger Kimberly, Kolesar Jill, Perlman Scott, Harrow Kim, Dukart Gary, Liang Chris, Jeraj Robert, Liu Glenn, Bruce Justine Yang
肿瘤
肿瘤免疫
发表日期：2018
文献求助 收藏

A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors

在针对晚期实体瘤患者的 I 期研究中，采用药效学指导的 PF-00337210 剂量选择

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-016-2958-1
Bruce, Justine Yang; LoRusso, Patricia M; Goncalves, Priscila H; Heath, Elisabeth I; Sadowski, Elizabeth; Shalinsky, David R; Zhang, Yanwei; Traynor, Anne M; Breazna, Aurora; Ricart, Alejandro D; Tortorici, Michael; Liu, Glenn
发表日期：2016
文献求助 收藏

Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.

采用 (18)F-3'脱氧-3'氟-L-胸苷正电子发射断层扫描/计算机断层扫描评估阿昔替尼在晚期恶性肿瘤患者中的药效学研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-015-2779-7
Bruce Justine Yang, Scully Peter Colin, Carmichael Lakeesha L, Eickhoff Jens C, Perlman Scott B, Kolesar Jill Marie, Heideman Jennifer L, Jeraj Robert, Liu Glenn
肿瘤
肿瘤免疫
发表日期：2015
文献求助 收藏

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

一项针对肾细胞癌和其他晚期实体恶性肿瘤患者的舒尼替尼联合贝伐单抗序贯治疗的I期药效学试验

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-013-2373-9
Bruce, Justine Yang; Kolesar, Jill M; Hammers, Hans; Stein, Mark N; Carmichael, Lakeesha; Eickhoff, Jens; Johnston, Susan A; Binger, Kimberly A; Heideman, Jennifer L; Perlman, Scott B; Jeraj, Robert; Liu, Glenn
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2014
文献求助 收藏

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate

一项 II 期研究，评估 2-甲氧基雌二醇纳米晶体胶体分散液单独使用以及与苹果酸舒尼替尼联合使用治疗舒尼替尼治疗进展的转移性肾细胞癌患者的疗效。

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-010-9618-9
Bruce, Justine Yang; Eickhoff, Jens; Pili, Roberto; Logan, Theodore; Carducci, Michael; Arnott, Jamie; Treston, Anthony; Wilding, George; Liu, Glenn
肿瘤
肾癌
肿瘤免疫
细胞生物学
发表日期：2012
文献求助 收藏